SunilSharmaMD

Gastrointestinal Cancer, Hematologic Oncology, Clinical Pharmacology

Physician in Chief, Translational Genomics Research Institute, Chief Translational Research, HonorHealth Research Institute, Professor of Medicine City of Hope Comprehensive Cancer Institute

Request Appointment

Overview of Dr. Sharma

I am a Board Certified Medical Oncologist and a physician scientist who specializes in treating gastrointestinal, neuroendocrine and rare tumors like mesotheliomas. My research interests include development of novel early phase clinical trials and discovery of novel anti-cancer therapies esp. those that target the epigenome and other interesting cancer targets.
My career has been eclectic and I consider myself as a senior academic physician executive with excellent leadership and broad development
skills, business acumen and track record of success. Here are some of my skills-
• World – recognized leader in early phase drug development and discovery
• Instrumental in advancing several drugs (biologics and small molecules) from pre-clinical
(discovery) evaluation through Phases I-III in oncology and immunology
• Academic expertise in Program Creation including starting and growing Phase 1 programs and Experimental Therapeutic Programs
• Leadership of Cancer Centers and PO1 grant filings
• Developed Cancer centers to Comprehensive status
• Extensive network for clinical research including Academia, Industry and Cooperative Groups
• FDA interactions from Phase 1 to Phase 3, IND to NDA filings

I have started many biotechnology companies. These include Beta-Cat Pharmaceuticals (Now Iterion Pharma), Salarius Pharmaceuticals (NSDX:SLRX) and Stingray Pharmaceuticals. I am on the Scientific Advisory Board of many biotechnology companies. I have a MBA from University of Massachusetts- Amherst.

I derive my inspiration from brave souls who face this disease and also from my mother who pioneered the development of oncology in India and was a trailblazer in her time.

Office
10510 N 92nd Street Suite 200
Scottsdale, AZ 85258
Book by Phone+1(480) 485-2948
Is this information wrong?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1990 - 1993
Delhi University College of Medical SciencesClass of 1988

Certifications & Licensure

AZ State Medical License 2017 - 2026
UT State Medical License 2009 - 2026
TX State Medical License 1995 - 2025
NV State Medical License 2004 - 2025
NY State Medical License 1998 - 2025
CA State Medical License 2018 - 2025
TN State Medical License 1993 - 1997
GA State Medical License 1993 - 1997
IL State Medical License 1993 - 1996
PA State Medical License 1993 - 1996
AL State Medical License Active through 1995
Join now to see all

Clinical Trials

KRAS Wild-type Metastatic Colorectal Cancer Trial Start of enrollment: 2009 Dec 01
Completed
Phase 1
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma Start of enrollment: 2010 May 01
Completed
Phase 1, Phase 2
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers Start of enrollment: 2010 Sep 01
Terminated
Phase 1, Phase 2
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies Start of enrollment: 2010 Dec 01
Completed
Phase 1
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Start of enrollment: 2012 Mar 01
Completed
Phase 1
Dose-Escalation and Safety Trial of YN968D1 Start of enrollment: 2012 Apr 01
Completed
Phase 1, Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors Start of enrollment: 2012 Apr 01
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Start of enrollment: 2013 Jun 01
Completed
Phase 1
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator Start of enrollment: 2013 Jun 24
Completed
Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Start of enrollment: 2014 Feb 01
Terminated
Phase 1
Regorafenib + Panitumumab for Colorectal Cancers Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Start of enrollment: 2014 Jul 28
Terminated
Phase 1
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Start of enrollment: 2015 Jun 17
Completed
Phase 1, Phase 2
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Start of enrollment: 2016 Oct 21
Completed
Phase 1
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Start of enrollment: 2020 Aug 31
Terminated
Phase 1, Phase 2
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 1, Phase 2
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 2
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Start of enrollment: 1999 Jun 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
Mohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S., Guo, L., Cho, H., Li, A., Behal, A., Mirzapoiazova, T., Massarelli, E., Koczywas, M., Arvan...> ;Science Advances. 2023 Oct 13
4 citations
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.
Martin Sattler, Isa Mambetsariev, Jeremy Fricke, Tingting Tan, Sariah Liu, Nagarajan Vaidehi, Evan Pisick, Tamara Mirzapoiazova, Adam G Rock, Amartej Merla, Sunil Shar...> ;Journal of Clinical Medicine. 2023 Mar 1
9 citations
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Christian Kollmannsberger, Herbert Hurwitz, Lyudmila Bazhenova, Byoung Chul Cho, David Hong, Keunchil Park, Karen L Reckamp, Sunil Sharma, Hirak Der-Torossian, James G...> ;Targeted Oncology. 2023 Jan 1
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D Basu, Laurie J Goodman, Audrey A Ozols, Janine R LoBello, Thomas Royce, Michael S Gordon, Erkut H Borazanci, Margaux A Steinbach, Jeffrey Trent,...> ;Oncotarget. 2022 Oct 20
24 citations
A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Niharika B. Mettu, Susanna Varkey Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert J. Stagg, Ann M. Kapoun, Leonardo...> ;Clinical Cancer Research. 2021 Nov 29
4 citations
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
D.S-W. Tan, Michael Thomas, D-W. Kim, Sebastian Szpakowski, Patrick Urban, Ranee Mehra, Laura Q.M. Chow, Sunil Sharma, Ben Solomon, Enriqueta Felip, D.R. Camidge, Joha...> ;Lung Cancer. 2021 Nov 20
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D. Basu, Laurie J. Goodman, Audrey A. Ozols, Janine LoBello, Thomas Royce, Michael S. Gordon, Erkut Borazanci, Margaux Steinbach, Jeffrey M. Trent...> ;Oncotarget. 2021 Aug 31
4 citations
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Moshe Lapidot, Abigail E Case, Ellen Weisberg, Chengcheng Meng, Sarah R. Walker, Swati Garg, Wei Ni, Klaus Podar, Yin P Hung, Ruben D. Carrasco, Aine Knott, Prafulla C...> ;British Journal of Cancer. 2021 Jun 4
4 citations
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein Co...
Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N. Bhalla, Serina Ng, Ryan Rodriguez del Villar, Kevi...> ;The Journal of Pharmacology and Experimental Therapeutics. 2021 May 18
57 citations
Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
Daneng Li, Sabrina Sedano, Rebecca Allen, Jun Gong, May Cho, Sunil Sharma> ;Cancers. 2019 Jun 18
SUMOYLATION REGULATES GROWTH FACTOR INDEPENDENCE (GFI)-1 IN TRANSCRIPTIONAL CONTROL AND HEMATOPOIESIS.
Andrade, D.,Velinder, M.,Singer, J.,Maese, L.,Bareyan, D.,Nguyen, H.,Chandrasekharan, M. B.,Lucente, H.,McClellan, D.,Jones, D.,Sharma, S.,Liu, F.,Engel, M. E.> ;Mol. Cell. Biol.. 2016 Mar 09
30 citations
HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
Santhana G. T. Devaraj, Warren Fiskus, Bhavin Shah, Jun Qi, Baohua Sun, Swaminathan P. Iyer, Sunil Sharma, James E. Bradner, Kapil N. Bhalla> ;Leukemia. 2016 Feb 1
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durab...
Gupta, S.,Gouw, L.,Wright, J.,Chawla, S.,Pitt, D.,Wade, M.,Boucher, K.,Sharma, S.> ;Invest New Drugs. 2016 Feb 22
A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion coh...
Werner, T. L.,Wade, M. L.,Agarwal, N.,Boucher, K.,Patel, J.,Luebke, A.,Sharma, S.> ;Invest New Drugs. 2015 Sep 15
In vitro acaricidal activity of Murraya koenigii (L.) Spreng (Rutaceae) extracts against synthetic pyrethroid-resistant Rhipicephalus (Boophilus) microplus.
Singh NK, Vemu B, Singh H, Prerna M, Daundkar PS, Sharma SK, Dumka VK> ;Parasitol. Res.. 2015-04-01
Neuropsychological test performance among healthy persons in northern India: development of normative data.
Waldrop-Valverde, D.,Ownby, R. L.,Jones, D. L.,Sharma, S.,Nehra, R.,Kumar, A. M.,Prabhakar, S.,Kumar, M.> ;J. Neurovirol.. 2015 Mar 19
2 citations
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of...
Sunil Sharma, Petronella O Witteveen, Martijn P Lolkema, Dagmar Hess, Hans Gelderblom, Syed A Hussain, Maria G Porro, Edward Waldron, Sue-Zette Valera, Song Mu> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 1
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus, W.,Sharma, S.,Shah, B.,Portier, B. P.,Devaraj, S. G.,Liu, K.,Iyer, S. P.,Bearss, D.,Bhalla, K. N.> ;Leukemia. 2014 Apr 05
BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD.
Fiskus, W.,Sharma, S.,Qi, J.,Shah, B.,Devaraj, S. G.,Leveque, C.,Portier, B. P.,Iyer, S.,Bradner, J. E.,Bhalla, K. N.> ;Mol. Cancer Ther.. 2014 Jul 24
5 citations
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors
Sunil Sharma, Carolyn D. Britten, Joanne E. Mortimer, Swarupa Kulkarni, Michelle Quinlan, Angela Liu, Jeffrey W. Scott, Daniel J. George> ;Cancer Chemotherapy and Pharmacology. 2014 Sep 6
Acquired subglottic stenosis: aetiological profile and treatment results.
Pookamala S, Thakar A, Puri K, Singh P, Kumar R, Sharma SC> ;J Laryngol Otol. 2014-07-01
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study.
Falchook, G.,Kurzrock, R.,Gouw, L.,Hong, D.,McGregor, K. A.,Zhou, X.,Shi, H.,Fingert, H.,Sharma, S.> ;Invest New Drugs. 2014 Jun 01
Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar, S.,Theisen, E. R.,Bearss, J.,Mulvihill, T.,Hoffman, L. M.,Sorna, V.,Beckerle, M.,Sharma, S.,Lessnick, S. L.> ;Clin. Cancer Res.. 2014 Jun 26
Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells.
Fiskus, W.,Sharma, S.,Qi, J.,Valenta, J. A.,Schaub, L. J.,Shah, B.,Peth, K.,Portier, B. P.,Rodriguez, M.,Devaraj, S. G.,Zhan, M.,Sheng, J.,Iyer, S. P.,Bradner, J. E.,B...> ;Mol. Cancer Ther.. 2014 Jan 18
36 citations
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma, Elisabeth G.E. de Vries, Jeffrey R. Infante, Corina N.A.M. Oldenhuis, Jourik A. Gietema, Lin Yang, Sanela Bilic, Katie Parker, Michael Goldbrunner, Jeffr...> ;Investigational New Drugs. 2014 Feb 1
Join now to see all

Abstracts/Posters

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells
Sunil Sharma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

TGen, Ashion and HonorHealth: Organoids Can Help Pinpoint the Right Therapies for Cancer PatientsJune 22nd, 2020
Arizona’s HonorHealth Research Institute First to Investigate Combination of Atovaquone & Azithromycin in COVID-19 PatientsMay 7th, 2020
24 Pancreatic Cancer Patients Will Attend Charity Golf EventOctober 26th, 2019
Join now to see all

Other Languages

Hindi

Hospital Affiliations

HonorHealth Scottsdale Shea Medical CenterScottsdale, Arizona

External Links

We fight pancreatic cancerhttps://www.12news.com/article/news/tgen-in-phoenix-helping-fight-pancreatic-cancer/75-1488eb7d-ba79-487d-a7ab-bffc096baf63

Insurance Accepted

Altius Provider Directory
BCBS Blue Card PPO
BCBS Massachusetts Blue Care Elect PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Please verify your coverage with the provider's office directly when scheduling an appointment